Resources for Food and Drug Administration (FDA)

FDA Adds Cancer Warning To Johnson and Johnson's Psoriasis Drug

www.allheadlinenews.com

The U.S. Food and Drug Administration on Friday said a drug from Johnson & Johnson appears effective at treating a severe skin disease, but warned that its extended use may raise the risk of cancer.

Long-term use of ustekinumab may lead to increased risk of tumor development in psoriasis patients, the federal agency said on its website. The agency added that it still needs more long-term safety data to decide whether the drug increases the risk of cancer.

On Tuesday, an FDA committee plans to seek advice on the drug from outside medical experts. Johnson & Johnson's Centocor Inc. unit is seeking approval for the drug to treat adults with chronic moderate to severe plaque psoriasis.

View the Resource

Share or bookmarklet this web page at: